CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drug - fiercebiotech.com
Source: fiercebiotech.com ·
CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drug fiercebiotech.comCSL to pay $355M upfront to co-develop Alentis’ kidney and liver drug Endpoints NewsCSL Agrees to Pay Up to $1.6 Billion in Rare Disease Drug Deal Bloomberg.comCSL strikes $1.6B deal with Alentis for experimental kidney, liver drug (CSLLY:OTCMKTS) Seeking AlphaCSL strikes rare disease drug deal worth up to $1.6…
BestAIBroker analysis
- Finance-aware sentiment: positive (+0.40 on a -1 to +1 scale).
- Event classification: OTHER.
- Market importance score: 24/100, weighting entity relevance, source credibility, multi-outlet coverage and recency.
- Symbols referenced: CSL.